Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1993 Mar;91(3):410–414. doi: 10.1111/j.1365-2249.1993.tb05917.x

Molecular analysis of C3 allotypes in patients with nephritic factor.

J E Finn 1, P W Mathieson 1
PMCID: PMC1554701  PMID: 8443964

Abstract

The autoantibody nephritic factor (NeF) leads to complement consumption in vivo and is associated with type II mesangiocapillary glomerulonephritis (MCGN II) and partial lipodystrophy (PLD). The third component of complement (C3) exists in two common allotypic forms, C3S and C3F, distinguished at the protein level by electrophoresis. An increased frequency of the rarer C3F allele has been reported in several autoimmune conditions, including one small series of patients with NeF. However, patients with NeF have low levels of circulating C3 so that allotyping at the protein level is difficult. The molecular basis of the S/F polymorphism has recently been established: a single base change at the DNA level encodes a single amino acid substitution at the protein level. A second polymorphism, closely linked to the first, is defined by the MoAb HAV 4-1, and is also due to a single base change. These polymorphisms can therefore be analysed at the DNA level. We have used the amplification refractory mutation system (ARMS), a modification of the polymerase chain reaction (PCR), to analyse these two C3 polymorphisms at the DNA level in 26 patients with NeF. The allele frequencies of C3S and C3F were 0.673 and 0.327 (predicted values 0.79 and 0.2, chi 2 = 4.813, P < 0.05), giving a relative risk of 2.1 for the development of NeF conferred by the presence of a C3F allele. The HAV 4-1 allele frequencies were (-) 0.71 and (+) 0.29, i.e. not significantly different than predicted from the linked C3S/F allele frequencies. This is the largest series of patients with NeF yet published, and our data confirm an association between C3F and NeF. Possible mechanisms for for this link are discussed.

Full text

PDF
410

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alper C. A., Propp R. P. Genetic polymorphism of the third component of human complement (C'3). J Clin Invest. 1968 Sep;47(9):2181–2191. doi: 10.1172/JCI105904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arvilommi H. Capacity of complement c3 phenotypes to bind on to mononuclear cells in man. Nature. 1974 Oct 25;251(5477):740–741. doi: 10.1038/251740a0. [DOI] [PubMed] [Google Scholar]
  3. Botto M., Fong K. Y., So A. K., Koch C., Walport M. J. Molecular basis of polymorphisms of human complement component C3. J Exp Med. 1990 Oct 1;172(4):1011–1017. doi: 10.1084/jem.172.4.1011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Charlesworth J. A., Williams D. G., Sherington E., Lachmann P. J., Peters D. K. Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest. 1974 Jun;53(6):1578–1587. doi: 10.1172/JCI107708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Daha M. R., Austen K. F., Fearon D. T. The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3bBb(C3NeF), and its release after decay of convertase function. J Immunol. 1977 Sep;119(3):812–817. [PubMed] [Google Scholar]
  6. Daha M. R., Fearon D. T., Austen K. F. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol. 1976 Jan;116(1):1–7. [PubMed] [Google Scholar]
  7. Davis A. E., 3rd, Ziegler J. B., Gelfand E. W., Rosen F. S., Alper C. A. Heterogeneity of nephritic factor and its identification as an immunoglobulin. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3980–3983. doi: 10.1073/pnas.74.9.3980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gewurz A. T., Imherr S. M., Strauss S., Gewurz H., Mold C. C3 nephritic factor and hypocomplementaemia in a clinically healthy individual. Clin Exp Immunol. 1983 Oct;54(1):253–258. [PMC free article] [PubMed] [Google Scholar]
  9. Graham D. E. The isolation of high molecular weight DNA from whole organisms or large tissue masses. Anal Biochem. 1978 Apr;85(2):609–613. doi: 10.1016/0003-2697(78)90262-2. [DOI] [PubMed] [Google Scholar]
  10. Koch C., Behrendt N. A novel polymorphism of human complement component C3 detected by means of a monoclonal antibody. Immunogenetics. 1986;23(5):322–325. doi: 10.1007/BF00398796. [DOI] [PubMed] [Google Scholar]
  11. McLean R. H., Winkelstein J. A. Genetically determined variation in the complement system: relationship to disease. J Pediatr. 1984 Aug;105(2):179–188. doi: 10.1016/s0022-3476(84)80110-9. [DOI] [PubMed] [Google Scholar]
  12. Newton C. R., Graham A., Heptinstall L. E., Powell S. J., Summers C., Kalsheker N., Smith J. C., Markham A. F. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989 Apr 11;17(7):2503–2516. doi: 10.1093/nar/17.7.2503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Oliveira D. B., Peters D. K. The immunogenetic basis of autoimmunity. Autoimmunity. 1990;5(4):293–306. doi: 10.3109/08916939009014713. [DOI] [PubMed] [Google Scholar]
  14. Rambausek M., van den Wall Bake A. W., Schumacher-Ach R., Spitzenberg R., Rother U., van Es L. A., Ritz E. Genetic polymorphism of C3 and Bf in IgA nephropathy. Nephrol Dial Transplant. 1987;2(4):208–211. [PubMed] [Google Scholar]
  15. Scott D. M., Amos N., Sissons J. G., Lachmann P. J., Peters D. K. The immunogloblin nature of nephritic factor (NeF). Clin Exp Immunol. 1978 Apr;32(1):12–24. [PMC free article] [PubMed] [Google Scholar]
  16. Sissons J. G., West R. J., Fallows J., Williams D. G., Boucher B. J., Amos N., Peters D. K. The complement abnormalities of lipodystrophy. N Engl J Med. 1976 Feb 26;294(9):461–465. doi: 10.1056/NEJM197602262940902. [DOI] [PubMed] [Google Scholar]
  17. Srivastava N., Srivastava L. M. Association between C3 complement types and Indian childhood cirrhosis. Hum Hered. 1985;35(4):268–270. doi: 10.1159/000153559. [DOI] [PubMed] [Google Scholar]
  18. Tedesco F., Tovo P. A., Tamaro G., Basaglia M., Perticarari S., Villa M. A. Selective C3 deficiency due to C3 nephritic factor in an apparently healthy girl. Ric Clin Lab. 1985 Oct-Dec;15(4):323–329. doi: 10.1007/BF03029146. [DOI] [PubMed] [Google Scholar]
  19. Teisberg P. High voltage agarose gel electrophoresis in the study of C 3 polymorphism. Vox Sang. 1970 Jul;19(1):47–56. doi: 10.1111/j.1423-0410.1970.tb01494.x. [DOI] [PubMed] [Google Scholar]
  20. Varade W. S., Forristal J., West C. D. Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III. Am J Kidney Dis. 1990 Sep;16(3):196–206. doi: 10.1016/s0272-6386(12)81018-3. [DOI] [PubMed] [Google Scholar]
  21. Welch T. R., Beischel L., Balakrishnan K., Quinlan M., West C. D. Major-histocompatibility-complex extended haplotypes in membranoproliferative glomerulonephritis. N Engl J Med. 1986 Jun 5;314(23):1476–1481. doi: 10.1056/NEJM198606053142303. [DOI] [PubMed] [Google Scholar]
  22. de Vries R. R., Meera Khan P., Bernini L. F., van Loghem E., van Rood J. J. Genetic control of survival in epidemics. J Immunogenet. 1979 Aug;6(4):271–287. doi: 10.1111/j.1744-313x.1979.tb00684.x. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES